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ABSTRACT 
 
 
 
As genomic sequencing becomes increasingly incorporated into clinical care, 
the patient informed consent process must successfully manage many ethical 
challenges, including whether to seek secondary findings and which results will be 
returned to the patient. The goal of the current study was to explore variation among 
existing informed consent forms for clinical whole exome sequencing (WES) in order 
to identify the level of consistency with the recommendations from the Presidential 
Commission for the Study of Bioethical Issues and the American College of Medical 
Genetics and Genomics (ACMG) regarding informed consent for clinical genome-
scale sequencing. 
Recommendations of the Presidential Commission for the Study of Bioethical 
Issues and ACMG were organized into a framework of 18 key points for analysis. In 
addition, 5 other points relevant to informed consent were identified from a 
preliminary review of the sampled forms and review of the literature. These were 
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assessed separately from the Bioethics Commission and ACMG list. Using these 
frameworks, content analysis was conducted on a sample of 18 informed consent 
forms for clinical WES downloaded from laboratory websites. 
For each of the individual Bioethics Commission and ACMG recommended 
consent items, the frequency of inclusion ranged from 11% to 100%. Among all 
forms in the sample, the average adherence to the complete list of 18 Bioethics and 
ACMG recommendations was 74.4%. For each of the 5 additionally identified items, 
the frequency of inclusion ranged from 5.6% to 50%. 
We observed considerable variability in the content of informed consent forms 
among the sample of 18 laboratories. This analysis can be useful to laboratories that 
provide clinical WES to create informed consent forms that they are in alignment 
with recommendations from the Bioethics Commission and ACMG. The 
development of a more standardized informed consent process could improve 
communication between clinicians and patients, increase understanding of genetic 
testing, and allow for increased data sharing. 
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CHAPTER 1 
INTRODUCTION 
Genomic analysis, including whole genome sequencing (WGS), whole exome 
sequencing (WES), and direct-to-consumer genetic testing (DTC), is becoming more 
useful and accessible to both physicians and individuals. Genomic sequencing can 
be considered in a variety of clinical contexts, including the diagnosis of rare 
diseases, the individualization of treatment (particularly in cancer), and 
pharmacogenomics (Botkin et al., 2015; Green et al., 2013). Medical professionals 
are using genomic testing for patients experiencing a “diagnostic odyssey,” cases 
with numerous unsuccessful attempts to establish a definite diagnosis (Tacik et al., 
2015). WGS and WES are useful methods for identifying complex hereditary 
disorders that can be difficult to diagnose clinically because of unusual presentations 
or rare occurrence (Lohmann & Klein, 2014; Tacik et al., 2015). The general public 
can also obtain personal genomic information, including disease predisposition and 
ancestry information, from companies that offer testing services. However, it is 
important to understand that genetic testing is not a simple tool but a complex 
practice (Buchbinder & Timmermans, 2011). 
WGS is a procedure to determine the order in which the bases are arranged 
within an individual’s DNA. The goal is to identify, annotate, and interpret variants in 
the sample by comparing it to a known reference sequence. WES consists of 
analyzing all of a genome’s coding exons, representing approximately 1% of the 
genome (Lohmann & Klein, 2014). WES is particularly useful for patients who have 
genetic disorders with profound and heterogeneous phenotypes and atypical and 
2 
 
incomplete presentations (Tacik et al., 2015). It is becoming more cost-effective and 
as a result more extensively applied (Tacik et al., 2015).  
As genomic sequencing becomes increasingly incorporated into clinical care, 
ethical challenges about the appropriate management of incidental findings are a 
growing concern (Crawford, Foulds, Fenwick, Hallowell, & Lucassen, 2013; Hull & 
Berkman, 2014; Wolf, 2015). “Incidental findings” refer to unexpected results that are 
unrelated to the indication for a particular test (Green et al., 2013; Roche & Berg, 
2015). “Secondary findings” is the term now recommended by the Presidential 
Commission for the Study of Bioethical Issues (2013) and adopted by the American 
College of Medical Genetics and Genomics (ACMG; 2015) for test results that are 
not the primary object of study but that are deliberately sought because they may 
have potential health importance for an individual and their biological relatives 
(ACMG, 2015; Bioethics Commission, 2013; Crawford et al., 2013; Hull & Berkman, 
2014; Roche & Berg, 2015; Weiner, 2014; Wolf, 2015). Important ethical issues 
posed by secondary findings include the role of patients in informed consent, 
whether clinicians will be expected to actively seek secondary findings, whether 
secondary findings for adult-onset disorders should be disclosed to children, and 
obligations of patients and physicians to disclose secondary findings to family 
members of patients (Hull & Berkman, 2014; McGuire & Gibbs, 2006; Wolf, 2015). 
The ACMG suggests an ethical duty to actively seek secondary findings in 
large-scale genetic sequencing any time it is used in the clinical setting, advising that 
clinically actionable secondary findings for 56 specific genes must be disclosed to 
patients regardless of the patient’s age (Green et al, 2013; Hull & Berkman, 2014; 
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Weiner, 2014). As the field of genomic medicine continues to evolve and more 
patients have the opportunity to undergo genomic testing, the clinical and ethical 
issues associated with the reporting of secondary findings will need ongoing 
evaluation (Hegde et al., 2015). 
General safeguards need to be put in place for informed consent for clinical 
genomic sequencing (McGuire & Gibbs, 2006). One suggested approach is to have 
a stratified informed consent process, which could help patients determine what type 
of results they would like to receive (e.g., with reproductive or life planning 
implications) and with whom they want their data shared (Egalite, Groisman, & 
Godard, 2014; McGuire & Gibbs, 2006; Weiner, 2014). There is also the 
corresponding “right not to know”, as patients could wish to not be informed of 
secondary findings (Egalite et al., 2014; Hull & Berkman, 2014; Weiner, 2014). The 
ACMG (2013) recommends that patients should have an opportunity to “opt out” of 
the analysis of medically actionable genes when undergoing clinical genome-scale 
sequencing. Consent and disclosure practices also need to take potential familial 
implications into account (Crawford et al., 2013; Hull & Berkman, 2014). 
Clinicians would benefit from guidelines on returning secondary findings and 
the development of infrastructure to support that process (Klitzman et al., 2013). The 
2013 Presidential Commission for the Study of Bioethical Issues recommended the 
creation of evidence-based practice guidelines and additional empirical research on 
return of results (Weiner, 2014). The development of a framework for reporting 
secondary findings will be an essential part of standardizing the informed consent 
process, improving communication between clinicians and patients, and increasing 
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understanding of genetic testing. Therefore, an empirical study of informed consent 
for clinical WES was conducted to evaluate the representation of recommendations 
of the Bioethics Commission and ACMG.  
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CHAPTER 2 
REVIEW OF LITERATURE 
Identification of incidental findings is not a new problem in medicine. 
Laboratory values or diagnostic imaging findings that require clinical action are 
commonly discovered incidentally (Berg et al., 2015; Hegde et al., 2015). Some may 
cause concern but are not actionable. Decisions regarding the return of medical 
incidental findings reflect consideration of the patient’s right to know, beneficence, a 
duty to warn, the clinical relevance of findings, and the potential for false-positive or -
negative results (Hegde et al., 2015; Hull & Berkman, 2014; Klitzman et al., 2013). 
As with diagnostic imaging incidental findings, the reporting of genomic secondary 
findings should seek to maximize the benefits (increasing the likelihood of true 
positive results) and minimize the harms (decreasing the likelihood of false positive 
results) (Green et al., 2013). 
The implications of secondary findings for the patient and first-degree 
relatives are varied. A secondary finding may provide relief to patients and families if 
it is negative for an altered gene associated with a high risk or certainty of hereditary 
disease (American College of Obstetricians and Gynecologists (ACOG), 2008; 
American College of Preventive Medicine (ACPM), 2010). However, a secondary 
finding with positive results indicating a high risk or certainty of hereditary disease 
may bring emotional burdens including feeling angry, depressed, anxious or guilty 
(ACOG, 2008; ACPM, 2010; Botkin et al., 2015). Consequences can also include 
family discord or social stigmatization (ACOG, 2008; ACPM, 2010; Botkin et al., 
2015). Family members may be faced with difficult reproductive choices for a finding 
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of carrier status for a disorder inherited in an autosomal recessive manner (ACOG, 
2008). The findings also cannot determine for the patient or their relatives the timing 
or severity of symptoms of a disorder (ACPM, 2010). 
Large-scale genomic sequencing is rapidly being integrated into clinical 
practice (Green et al., 2013; Bioethics Commission, 2012). When WGS/WES is 
used, the likelihood of identifying secondary findings increases significantly 
(Bioethics Commission, 2013; Hegde et al., 2015). The current estimation for the 
likelihood of finding a medically actionable secondary finding as a result of WES is 1-
3% (Botkin et al., 2015). In order to minimize the likelihood of discovering secondary 
findings, the American Society of Human Genetics (ASHG) recommends targeted 
tests or selective sequence analysis when the clinical challenge can be addressed 
through such an approach (Botkin et al., 2015).  
Recommendations of the Presidential Commission  
for the Study of Bioethical Issues 
 
The Presidential Commission for the Study of Bioethical Issues (referred to as 
the Bioethics Commission throughout this report) has issued guidance for clinicians 
regarding the integration of WGS into clinical care (Bioethics Commission, 2012; 
Bioethics Commission, 2013). These recommendations are grounded in the 
principles of respect for persons, specifically “public beneficence, responsible 
stewardship, intellectual freedom and responsibility, democratic deliberation, and 
justice and fairness” (Bioethics Commission, 2012, p. 3). The Bioethics Commission 
recognized that a robust informed consent process is necessary for ethical clinical 
care. Given the complexities of WGS, this process is more difficult than for common 
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diagnostic tests. According to the Bioethics Commission (2013), the consent process 
for genome-scale sequencing should include: 
…information about what whole genome sequencing is; how data will 
be analyzed, stored, and shared; the types of results the patients and 
participants can expect to receive, if relevant; and the likelihood that 
the implications of some of these results might currently be unknown, 
but could be discovered in the future (p.7). 
The Bioethics Commission (2013) acknowledged that context-specific 
differences allow for variance between consent models. The process should 
effectively inform individuals without undermining their ability to make voluntary 
choices, but there is no imperative to use one kind of consent model (Bioethics 
Commission, 2012). However, as large amounts of patient data are being collected 
into the infrastructure that supports precision-medicine, known as the “learning 
healthcare system,” standardized systems can facilitate health information exchange 
so that data can be more easily aggregated and studied (Aronson & Rehm, 2015; 
Bioethics Commission, 2012; Reinke, 2015).  
Recommendations of the American College of  
Medical Genetics and Genomics  
 
The American College of Medical Genetics and Genomics (ACMG; 2013) has 
created a set of recommendations for the situation in which a physician orders 
genome-scale sequencing for a clinical indication, based on available evidence of 
clinical validity and utility. Acknowledging a lack of sufficient data about benefits, 
risks, and costs of disclosing secondary findings, the ACMG recommendations are 
based upon clinical consensus among its members (Green et al., 2013). The ACMG 
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recommends that for any evaluation of clinical genome sequencing, a minimum list 
of 56 genes be examined and the pathogenic and likely pathogenic variants reported 
to the ordering clinician. Regarding the informed consent process, the ACMG (2013) 
recommends addressing issues including interpretive uncertainty, privacy, and 
possible impact on other family members. The ACMG (2013) recommends the 
development of an appropriate metric to guide the reporting of secondary findings 
(Berg et al., 2015; Green et al., 2013).  
Informed Consent Procedures for Clinical  
Genomic Sequencing Vary  
 
Earlier studies of consent forms among sites engaged in genomic sequencing 
research found discrepancies and omissions in the descriptions of potential findings, 
types of results to be returned or not, and the role of patient preferences (McGuire & 
Gibbs, 2006; Roche & Berg, 2015). McGuire and Gibbs (2006) found that the 
consent process for most genomic sequencing research simply stated that genetic 
analysis would be performed, without specifically explaining the analysis or with 
whom results would be shared. Roche and Berg (2015) described the content of 
consent forms that were created based on hypothetical situations rather than 
empirical data and concluded the management of secondary findings revolved 
around perceived differences in responsibilities of practitioners and preferences of 
participants (Roche & Berg, 2015).  
Providing a patient with informed consent requires a balance between 
information overload and uninformed consent (Rigter et al., 2013). There are many 
attributes that may be significant to a patient’s informed decision to learn secondary 
findings, including lifetime risk, treatability, seriousness, and cost (Roche & Berg, 
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2015). Procedures for providing informed consent vary in whether patients are given 
an opt-in, opt-out, or stratified option for receiving secondary findings. With an “opt-
in” option, the default procedure of the laboratory is not to seek secondary findings 
and patients actively choose to receive secondary findings; if they opt-in, results will 
be returned. With an “opt-out” option, the default procedure of the laboratory is to 
seek and report secondary findings, and patients actively choose not to receive 
these results; if they opt-out, results will not be returned. With a stratified consent 
process, the laboratory does not have a default procedure, allowing patients who 
receive clinical genomic sequencing options about what genes will be reported, what 
secondary findings may be returned, and with whom they want their data shared 
(McGuire & Gibbs, 2006).  
There is conflicting guidance about whether to seek and how to manage 
secondary findings (Gutmann, 2013). The management of secondary findings and 
the extent to which laboratories are obliged to seek and disclose an expanding list of 
genetic results of varying significance pose important ethical challenges (Hull & 
Berkman, 2014). While variants are ubiquitous in the genome, the presence of 
known pathogenic variants must be actively sought from among the vast number of 
unknown or non-pathogenic genomic variants in order to be identifiable and 
reportable (Roche & Berg, 2015). Most secondary findings have limited medical 
actionability, thereby leading to a lack of consensus regarding their routine 
disclosure (Roche & Berg, 2015). The ACMG recommends required reporting of 
mutations found in 56 genes on the “minimum list,” regardless of the indication for 
which the clinical sequencing was ordered (Green et al., 2013). In contrast, guidance 
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from both the ASHG and the Bioethics Commission finds no ethical duty for 
clinicians to search for genetic results that are not relevant to the clinical indication 
for sequencing (Botkin et al., 2015; Weiner, 2014).  
Ethical Considerations for the Provision of  
Secondary Findings to Children 
 
The standards for clinical genomic sequencing recognize a distinction 
between providing secondary findings to adults versus children and adolescents 
(Green et al., 2013). One important dilemma is that federal privacy laws are 
inconsistent in defining the age of consent (Bioethics Commission, 2012). A second 
consideration is that scientific advancements during a child’s lifetime can compound 
the current unknown risks raised by genome-scale sequencing (Bioethics 
Commission, 2012). Third, sequencing data obtained from a minor could be widely 
shared before they reach an age to self-determine data sharing limits, thereby 
diminishing their autonomy (Bioethics Commission, 2012).  
Clinical practice guidelines generally recommend that only information that is 
clearly actionable in childhood be disclosed and that the decision to learn about 
adult-onset conditions be delayed until the age of majority out of respect for the 
child’s developing autonomy (Hull & Berkman, 2013; Roche & Berg, 2015). In 1995, 
the ACMG and ASHG issued a joint recommendation that in the absence of medical 
benefits to the child, testing should be deferred until adulthood, particularly for adult-
onset conditions or for carrier status for reproductive decision making (Botkin et al., 
2015). However, the ACMG recently changed this longstanding guidance with the 
reasoning that the potential benefit to the future health of the child outweighs ethical 
concerns of discovering secondary findings for treatable adult-onset conditions. The 
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ACMG also reasoned that the disclosure of a secondary finding of cancer risk for the 
child may indicate high-risk of cancer for the parent, and the child is protected if the 
parent is informed. The ACMG now recommends that seeking and reporting 
secondary findings not be limited by the age of the person being sequenced (Green 
et al., 2013). The ASHG recommends the return of results to parents only if the 
secondary findings have clinical utility for the child (Botkin et al., 2015). It is also 
recommended that parents be allowed to decline to receive secondary findings in 
advance of genomic testing, but if a secondary finding with urgent and serious 
implications for the child’s health is found, the clinician is advised to communicate 
those findings to parents regardless of their preference not to know (Botkin et al., 
2015). Additionally, the ASHG recommends that genomic testing in children should 
include a long-term communication plan for all results (Botkin et al., 2015). 
Ethical Considerations for Secondary Findings  
and the Patient’s Relatives  
 
Information about genetic variants has health implications for the patient’s 
family, since first-degree biological relatives share 50 percent of their genes 
(Bioethics Commission, 2013; Egalite et al., 2014; Wolf, 2015). Genetic studies 
targeting specific genes in an affected patient may reveal genetic variants relevant to 
the patient’s immediate family (Egalite et al., 2014). In this situation, the clinician is 
confronted with conflicting duties to protect the patient’s privacy and to warn 
biological relatives of shared risk (Rigter et al., 2013; Wolf, 2015). Decisions depend 
on the specific context of a given case.  
Genomic sequencing may reveal that a patient’s first-degree biological 
relative has, is at risk for, or is a carrier of a specific disease (Bioethics Commission, 
12 
 
2013; Egalite et al., 2014; Wolf, 2015). Like other medical information, physicians 
have stringent responsibilities to protect the privacy of a patient’s genetic data as a 
matter of law, ethics and institutional policy, but professional guidance varies (Ross 
et al, 2013; Wolf, 2015). The Health Insurance Portability and Accountability Act 
(HIPAA) protects the privacy of health information, including a patient’s genetic 
information, for 50 years after an individual’s death (McGuire & Gibbs, 2006; Wolf, 
2015). The ASHG acknowledges that physicians have a privilege, but not an 
obligation, to warn relatives of possible genetic risks in cases where the patient fails 
to voluntarily disclose to relatives; serious and foreseeable harm is highly likely to 
occur; at-risk relatives are identifiable; and, the disease is preventable, treatable, or 
early monitoring will reduce the risk of dying from the related condition (Wolf, 2015). 
In contrast, the Institute of Medicine advises that genetic risk information should be 
withheld so as to avoid family disruption (ACOG, 2014; Buchbinder & Timmermans, 
2011). Moreover, the American Medical Association has argued that physicians 
have an obligation to pay almost unlimited respect to a patient’s confidentiality 
(ACOG, 2014).  
A relatively common incidental consequence of genomic testing is the 
detection of misattributed parentage, with estimated rates of 1–10% from various 
studies (Botkin et al., 2015; Ross et al., 2013). Recommendations for the disclosure 
of misattributed parentage are diverse and unsettled (Botkin et al., 2015). Arguments 
in favor of disclosure of paternity findings center on the patient’s right to know, 
avoiding paternalism, and the duty of physicians to be truthful (Botkin et al., 2015). 
Arguments opposing disclosure conclude that because of the potential for harm to 
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individuals and the family, misattributed parentage should not be disclosed to either 
the mother or the father (Botkin et al., 2015). Pretest counseling should alert parents 
or guardians to this possibility (Ross et al, 2013). 
Legal Considerations 
An important possible consequence of genomic sequencing is how the results 
might affect future insurance coverage (ACOG, 2014; Apold & Downie, 2011; 
OHRP, 2009). The Genetic Information Nondiscrimination Act (GINA) (2008) 
provides federal protection from genetic discrimination in employment and health 
insurance, but not long-term care, disability, or life insurance, potentially leaving 
patients unable to obtain this insurance after genomic sequencing (Hegde et al., 
2015; OHRP, 2009). The Office for Human Research Protections (OHRP) 
recommends that the informed consent process provide information describing the 
protections provided by GINA (OHRP, 2009).  
Patent law and controversies over intellectual property in biotechnology and 
pharmaceutical industries, and particularly over patenting genes, have affected the 
provision of genomic sequencing results to patients (Sherkow & Greely, 2015). 
Myriad Genetics, Inc. aggressively enforced patent rights to the BRCA1 and BRCA2 
genes, bringing litigation against clinicians performing BRCA1- and BRCA2-based 
cancer risk assessments (Sherkow & Greely, 2015). The U.S. Supreme Court case 
of Association for Molecular Pathology v. Myriad Genetics, Inc. broke the company’s 
patent-based monopoly on BRCA1 and BRCA2 testing in the United States 
(Sherkow & Greely, 2015). “Gene patents may be officially dead in the United 
States, but could live on, at least weakly, in other countries” (Sherkow & Greely, 
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2015, p. 175). Concerns over intellectual property rights may be reflected in 
informed consent procedures for which results will be provided to patients 
undergoing genomic sequencing tests.  
Need for Guides for Standard Practices for  
Secondary Findings 
 
The development of an appropriate framework to guide the identification and 
disclosure of secondary findings is needed (Berg et al., 2015; Green et al., 2013; 
Gutmann, 2013). Guidance is sought on what information should be discussed 
preceding the test, whether clinicians will be expected to actively look for secondary 
findings, options for patients to choose broad data return or to opt-out, which results 
are mandatory to disclose regardless of patient choice, and consequences for 
children and relatives (Hull & Berkman, 2014; Rigter et al., 2013; Weiner, 2014). 
Practice guidelines must acknowledge the complexity of genomic data (Weiner, 
2014).  
Prior research provides frameworks to consider for the development of 
informed consent guidelines for identifying and reporting secondary findings. Berg et 
al. (2013) proposed a system that assigns genes to bins according to features such 
as clinical actionability, clinical validity, potential to cause harm, and reproductive 
implications. Building on this work, Berg et al. (2015) established five core 
characteristics of clinical actionability: severity, likelihood, efficacy of intervention, 
burden of intervention, and knowledge base about the gene, condition, and 
intervention. These characteristics are scored on a continuum, not as a binary state 
(Berg et al., 2015). Another possible framework approach is to define categories by 
the nature of the condition, differentiating between early and late-onset diseases, the 
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level of risk, burden of the disease, and options for treatment or prevention (Rigter et 
al., 2013). 
Given the inconsistency in guidance for the identification and disclosure of 
secondary findings, a standard framework that will allow for evidence-based 
decisions about benefits and risks of reporting secondary findings needs to be 
developed (Green et al., 2013; Weiner, 2014). Common practices need to be put in 
place to encourage understanding of and trust in clinical genomic sequencing 
(McGuire & Gibbs, 2006). The development of standard practices for informed 
consent and return of secondary findings will permit empirical study of the benefits 
and challenges associated with clinical genomic sequencing, and facilitate evidence-
based recommendations to patients during pre-test informed consent and post-test 
counseling (Berg et al., 2013; Green et al., 2013; McGuire & Gibbs, 2006).  
In order to evaluate the penetrance of the Bioethics Commission’s and 
ACMG’s recommendations for informed consent for clinical WES, an empirical study 
of informed consent models for clinical WES was undertaken. We hypothesized that 
variability would be found in models of informed consent for clinical WES, and for 
seeking and reporting of secondary findings, as well as the extent to which 
recommendations from the Bioethics Commission and ACMG are incorporated into 
the process of informed consent. The study objectives are aligned with the 
emergence of precision medicine and the learning healthcare system that supports 
it, through improved informed decision making for the identification and reporting of 
secondary findings and creation of a standard framework to guide informed consent 
(Aronson & Rehm, 2015; Reinke, 2015; Wiley et al., 2016).  
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CHAPTER 3 
METHODOLOGY 
To test the hypothesis that variability would be found in models of informed 
consent for clinical WES, consent forms were evaluated using a content analysis 
matrix. The objective of the analysis was to identify the extent to which patient 
consent is guided by recommendations from the Bioethics Commission and the 
ACMG.  
Data Collection  
We collected a purposeful convenience sample of informed consent forms for 
clinical WES. We identified laboratories that conduct clinical WES from the National 
Center for Biotechnology Information’s Genetic Testing Registry 
(http://www.ncbi.nlm.nih.gov/gtr/), Gene Tests (https://www.genetests.org/), and 
NextGxDx (https://www.nextgxdx.com). Each of these sites was searched for 
Clinical Laboratory Improvement Amendment (CLIA) certified laboratories in the 
United States that provide clinical WES. Laboratories that provide tests for specific 
genes or conditions and those that conduct WES only for research purposes were 
excluded.  
Between January and February 2016, we identified 25 laboratories registered 
with the sites listed above as providing clinical WES. We accessed each website 
and found two of these laboratories provided WES only for research, not clinical, 
purposes. We were able to download informed consent forms from 18 of the 
remaining 23 organizations (78%).  
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Document Description and Case Definition 
We found a range of documents and addendums for provision of informed 
consent, including: ‘Patient Consent Form’, ‘Consent Form, Proband Only’, ‘Consent 
Form, Family Trio’, ‘Test Requisition Form’, ‘Expanded Secondary Findings Request 
Form’, ‘Raw Sequence Data Consent Form’, and ‘Authorization for Participation in a 
Research Protocol’. Given the variation in forms, the combination of documents from 
each organization was organized to comprise a unit of analysis as they would be 
presented to a patient (i.e. primary consent template with addendums).  
Our final sample was comprised of 18 cases combining 29 different informed 
consent forms and addendums. The informed consent units were categorized by 
institution type as commercial laboratories (n=8), or academic laboratories affiliated 
with a hospital or university (n=10) (Table 1). 
 
 
Table 1  
Type of Laboratory among Laboratories Providing Clinical  
Whole Exome Sequencing 
Laboratory Type N % 
Commercial   8     44.4 
Academic 10     55.6 
Total 18 100 
 
 
 
Data Analysis Process 
We applied content analysis to the units of consent in order to identify and 
describe characteristics of the documents that align with recommendations from the 
Bioethics Commission and ACMG. The first step was to create a content analysis 
matrix to evaluate the sample of informed consent forms. Recommendations from 
18 
 
two Bioethics Commission reports pertaining to informed consent, Privacy and 
progress in whole genome sequencing (2012), and Anticipate and communicate: 
Ethical management of incidental and secondary findings in the clinical, research, 
and direct-to-consumer contexts (2013), and two ACMG policy statements, ACMG 
recommendations for reporting of incidental findings in clinical exome and genome 
sequencing (Green et al., 2013), and Points to consider for informed consent for 
genome/exome sequencing (2013), were analyzed (Appendices A-D). Key points 
that should be included in informed consent for WES were identified. These key 
points were organized by common themes (Table 2).  
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Table 2  
Bioethics Commission and ACMG Recommended Key Points and Common Themes 
Recommendation Key Points Common Theme 
Privacy & Practice, 2 Briefly describe whole genome sequencing and analysis Description of WES 
Privacy & Practice, 2 State how the data will be used in the present study Purpose of WES 
Privacy & Practice, 2 
ACMG 
Define benefits and potential risks 
Potential benefits and risks of exome sequencing 
Benefits and risks of 
WES 
Privacy & Practice, 2 
ACMG 
There might be unknown future risks 
Limitations of testing 
Uncertainty of 
results 
ACMG Policies regarding re-contact of referring physician as new 
knowledge is gained about significance of particular results 
Follow-up if results 
are updated 
Privacy & Practice, 3 To whom the findings will be communicated Results returned to 
whom 
Privacy & Practice, 2 
 
Privacy & Practice, 3 
Anticipate & Communicate, 1 
Anticipate & Communicate, 6 
ACMG 
What data and information, if any, might be returned to the 
individual 
The scope of communicated findings 
What findings will be returned 
The scope of findings that will be communicated 
Expected outcomes of testing 
Describe results 
returned to proband 
Anticipate & Communicate, 1 
ACMG 
What findings will not be returned 
Types of results that will not be returned 
Results excluded 
from report 
Privacy & Progress, 3 
Anticipate & Communicate, 1 
 
Anticipate & Communicate, 6 
 
ACMG 
Incidental findings are likely to be discovered 
Incidental and secondary findings that are likely to arise or be 
sought from the tests and procedures conducted 
Incidental and secondary findings are a possible, or likely, result of 
the tests or procedures being conducted 
Likelihood and type of incidental results that may be generated 
Define incidental/ 
secondary findings 
Privacy & Progress, 3 
Anticipate & Communicate, 1 
 
Whether these findings will be communicated 
Plan for disclosing and managing incidental and secondary 
findings 
Options for ACMG 
minimum list 
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Recommendation Key Points Common Theme 
ACMG 
 
 
Anticipate & Communicate, 6 
Incidental/secondary findings may have high clinical significance 
for which interventions exist to prevent or ameliorate disease 
severity 
Respect a patient’s preference not to know about incidental or 
secondary findings to the extent consistent with a clinician’s 
fiduciary duty 
Anticipate & Communicate, 6 
ACMG 
Steps to be taken upon discovery of incidental findings 
Potential implications for family members 
Return secondary 
findings for minors 
Anticipate & Communicate, 6 
ACMG 
Steps to be taken upon discovery of incidental findings 
Potential implications for family members 
Disclose secondary 
findings to relatives 
Privacy & Practice, 1 
Privacy & Practice, 2 
 
Privacy & Practice, 2 
How these data might be used in the future 
How the data might be used in the future, i.e. for research 
purposes 
Extent to which the individual will have control over future data use 
Request to use 
sample for research 
Privacy & Practice, 1 
ACMG 
 
ACMG 
How these data might be used in the future 
Whether individually identifiable results may be provided to 
databases 
Permitted to opt-out of disclosing individually identifiable results to 
databases 
Sample may be 
shared in databases  
Privacy & Practice, 1 Who has access to whole genome sequences and other data 
generated in the course of clinical sequencing 
Who has access to 
sequence data 
ACMG 
 
ACMG 
Before initiating exome sequencing, counseling should be 
performed by a genetic counselor 
The clinician should also provide posttest counseling 
Opportunity for 
genetic counseling 
ACMG Information derived: carrier status  Disclose carrier 
status for recessive 
disorders 
ACMG Information derived: ancestry Risk discovery of 
misattributed 
parentage 
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During the review of the literature and preliminary scanning of consent 
documents, other key points for consent were identified in addition to those 
recommended by the Bioethics Commission and ACMG. These items were included 
in the coding framework as separate items for analysis (Table 3).  
 
 
Table 3 
Recommended Key Points for Informed Consent Derived from Review 
of the Literature and Preliminary Scan of Sample Forms 
Key Points 
Return raw data file 
Transfer results to other health care provider 
Samples from NY destroyed in 60 days  
Risk: Insurance discrimination/Genetic Information Nondiscrimination Act (GINA) 
Some genetic information is proprietary 
 
 
 
The key points of all recommended consent guidance were structured into a 
matrix for evaluating and coding the content of each sample unit (Table 4). 
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Table 4 
Content Analysis Coding Matrix 
Bioethics & ACMG Recommendation Key Points 
1.  Description of WES 
2.  Purpose for WES 
3.  Benefits and risks of WES 
4.  Uncertainty of results 
5.  Follow-up if results are updated  
6.  Results returned to whom 
7.  Describe results returned to proband 
8.  Results excluded from report 
9.  Define incidental/secondary findings  
10.  Options for ACMG minimum list 
11.  Return secondary findings for minors 
12.  Disclose secondary findings to relatives 
13.  Disclose carrier status for recessive disorders 
14.  Sample may be shared in databases  
15.  Request to use sample for research 
16.  Who has access to sequence data 
17.  Opportunity for genetic counseling 
18.  Risk discovery of misattributed parentage 
Other  
1.  Transfer results to other health care provider 
2.  Return raw data file 
3.  Samples from NY destroyed in 60 days 
4.  Risk: insurance discrimination/GINA 
5.  Some genetic information is proprietary 
 
 
 
During the second step, the cases were analyzed using the coding matrix. 
Each of the 29 documents was read and language addressing each theme was 
highlighted and coded. This step was then repeated twice for all documents as a 
confirmation check that the matrix was applied consistently and accurately. Each 
form was reviewed three times.  
Descriptive statistics were used to describe the overall sample and 
differences between types of institution. The nonparametric statistical method of 
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Fisher’s Exact test was used to compare the significance of differences of frequency 
of each key point between the two categories of institutions. 
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CHAPTER 4 
RESULTS 
Recommendations of Bioethics Commission and ACMG 
We found recommendations of the Bioethics Commission and ACMG present 
in all cases, to varying degrees. The frequency of inclusion of the 18 Bioethics and 
ACMG recommendations ranged from 11 to 17 items (Figure 1). The median 
frequency of inclusion of these 18 recommendations was 14 items.  
 
 
 
Figure 1. Number of Bioethics and ACMG Recommendations per Laboratory  
by Laboratory Type 
 
 
 
Among all forms in the sample, the average adherence to the complete list of 
18 Bioethics and ACMG recommendations was 74.4%, with academic laboratories 
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averaging 76.7% completeness and commercial laboratories averaging 72.2% 
completeness (Figure 2).  
 
 
Figure 2. Average Adherence to the Complete List of Bioethics Commission and 
ACMG Recommendations 
 
 
 
Examples of content language identified for each of the key points of the 
Bioethics Commission and ACMG recommendations are presented in Table 5. 
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Table.5 
 
Examples of Content Identified as Addressing Bioethics Commission and ACMG Recommendations 
Recommendation Example Consent Form Content 
1. Description of WES [The test] attempts to evaluate the protein-coding regions of the human genome, which 
represents approximately 20,000 genes. These regions of DNA are referred to as 'exome'. 
The exome accounts for approximately 2% of the genome and comprises the majority of 
DNA variations that cause human disease. Exome sequencing is a useful and powerful tool 
for diagnostic applications and has been utilized to identify mutations in disorders that are 
both genetically and phenotypically heterogeneous and to identify mutations in genes 
associated with Mendelian disorders. 
2. Purpose for WES The purpose of WES is to identify genetic cause(s) of the patient's health issues. 
3. Benefits and risks of 
WES 
Benefits: identify a cause for your health condition or symptoms, assist you and your 
healthcare provider in choosing the best treatment for you, determine recurrence risk of 
disease in your family, identify predisposition to disease 
Risks: information might reveal: genetic risks for diseases that may develop later in life, 
disease unrelated to the primary reason for ordering the test, disorders that do not have 
current treatment, other unexpected familial relationships 
4. Uncertainty of results Although there are some entire genes that we may not be able to capture and sequence in 
a particular patient, in general we expect that there may be small portions of different genes 
that are not amenable to evaluation. 
Information about the human genome is not yet complete. It is possible that we will not 
recognize the cause of a child's disease even though we may identify the presence of the 
variant in the DNA. This is because the functions of many genes are completely unknown at 
this time. 
I have been informed that the sensitivity of the [test] is not 100% and that the cause of the 
disease in my child may not be identified by this analysis. 
5. Follow-up if results are 
updated 
By signing this consent, you give [the laboratory] permission to retain the genetic 
information generated by this test and to contact your physician if [the laboratory] learns 
new information about the genetic variants detected by this test that affects your reported 
test results. [The laboratory] will make reasonable efforts to contact your physician in these 
instances. It is the responsibility of the patient to maintain current contact information with 
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Recommendation Example Consent Form Content 
the healthcare provider so that the patient may be advised of any changes to their test 
results. 
6. Results returned to 
whom 
The results of this test will be kept confidential and will be released only to the physician(s) 
ordering the test or other persons authorized by you, in writing, unless otherwise required 
by federal and state law. 
7. Describe results 
returned to proband 
[The laboratory] will report on genetic variants that have been reported to be pathogenic, 
predicted to be pathogenic, possibly pathogenic as well as unclassified variants in 
established genes for the clinical features/suspected condition indicated for the patient. In 
addition, truncating pathogenic variants and variants that have been previously reported to 
be pathogenic or possibly pathogenic in genes hypothesized to be related to the cause of 
the patient's phenotype will also be reported. 
8. Results excluded from 
report 
The report will not contain information on variants associated with drug metabolism, 
common variants associated with modest changes in the risk of common diseases, or 
variants in genes that have not yet been linked to diseases in humans. 
9. Define 
incidental/secondary 
findings  
The test may find genetic changes that tell us that you/your child are at risk for diseases 
other than your/your child's condition, such as cancer risk. These changes are often called 
"incidental" or secondary findings. 
10. Options for ACMG 
minimum list 
The ACMG have published guidelines for the reporting of these types of medically 
actionable or incidental findings (PMID: 23788249). These guidelines include a list of 
genes, which may be updated periodically, that have been determined to be considered 
medically actionable and therefore laboratories should seek and report pathogenic variants 
in these genes. In accordance with an update to this policy statement, there is the option to 
opt out of receiving pathogenic variants information if identified in the genes listed in ACMG 
policy statement. It will not be reported on either the focused or the expanded report. 
11. Return secondary 
findings for minors 
Incidental findings that cause a childhood onset disorder where medical intervention can 
prevent or decrease the effect of a disease will always be included in the laboratory report. 
12. Disclosure secondary 
findings to relatives 
This test could reveal information about the health of your relatives, such as their chance of 
developing certain disorders. Such information could be unexpected, or it could explain a 
medical condition in your family. If the test finds a genetic change that may be important to 
your family's health, you/your child's healthcare provider will ask you to tell your family 
members about it. 
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Recommendation Example Consent Form Content 
13. Disclose carrier status 
for recessive disorders 
Carrier status for autosomal recessive conditions (e.g., Cystic Fibrosis). A recessive 
condition is one in which two pathogenic variants in the same gene are required in order to 
show symptoms of the disease (one variant is inherited from each parent). Someone who 
has only one pathogenic variant does not show symptoms and is called a carrier. However, 
if we find a pathogenic variant in a recessive gene that is related to the patient's phenotype, 
we will report it as a diagnostic finding. You can choose whether or not you want us to 
report carrier status in genes that are not related to the patient's phenotype. The [test] is not 
designed to be a comprehensive carrier test. 
14. Sample may be shared 
in databases  
The data used to generate the final report while performing [the test] will be saved for at 
least two (2) years after testing is completed and the report is issued to your medical 
professional, your child's medical professional or the medical professional for the patient for 
whom you are legal guardian, as applicable, who ordered this test. In addition, if you give 
your permission below, [the laboratory] may retain de-identified sequence, variants, and 
clinical information in the databases that [the laboratory] uses to generate test results, and 
deposit such de-identified information in appropriate public databases e.g. ClinVar, with the 
goal of improving diagnosis for future families and parents. 
15. Request to use sample 
for research 
There may be research studies that you may be eligible for and may be of interest to you. If 
the "yes"/contact option is chosen please complete the additional information requested. 
Please note that if neither box is checked the laboratory will default to the "no"/no contact 
option. 
Yes, [the laboratory] may share my contact information with researchers who have IRB 
approved research study for which I may be eligible for participation. There is no obligation 
to participate if contacted. No information, other than the contact information below, will be 
provided to the researcher. 
No, I do not wish to be contacted regarding participation in research studies. 
16. Who has access to 
sequence data 
Your genomic sequencing report will list medically important genetic changes that were 
found by the genomic sequencing test. This report containing your test results as well as 
any updates to those results will become part of your child's permanent electronic medical 
record and be made available to any healthcare provider treating you now or in the future. 
The laboratory will not initially deposit your complete genetic sequence into your medical 
record. However, it is possible that this policy will change in the future in which case your 
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Recommendation Example Consent Form Content 
complete genetic sequence may be incorporated into your permanent medical records. 
17. Opportunity for genetic 
counseling 
Given the complexity of the [test], genetic counseling and informed consent by a trained 
medical geneticist or genetic counselor is required prior to and after undergoing this testing. 
Informed consent is a process that provides education about genetics, and the options, 
benefits, limitations, and consequences of genetic testing. Genetic counseling provides the 
patient with informed consent prior to the decision to undergo testing and with the 
opportunity to review the results of the test in detail. 
18. Risk discovery of 
misattributed parentage 
There is a risk that you may learn other genetic information about you or your family 
members that is not related to any specific medical concern(s). Learning about this 
information might cause anxiety and psychological stress. As an example, this test may 
reveal non-paternity and non-maternity (where the father or mother is not the biological 
parent) or other unexpected familial relationships. 
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The adherence to each of the individual Bioethics Commission and ACMG 
recommendations ranged from 11.1% to 100% (Figure 3).  
 
 
Figure 3. Adherence to Individual Bioethics and ACMG Recommendations 
for 18 Laboratories 
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All of the informed consent forms disclosed that the results may be uncertain 
due to limitations of the test, such as DNA changes that are not detected with WES 
and/or limited understanding of detected changes in some gene sequences. Nearly 
all consent forms (94.4%) included a description of WES, stated to whom results 
would be returned, defined secondary findings, explained options for receiving 
results for the ACMG minimum list, discussed opportunities for pre- and/or posttest 
genetic counseling, and disclosed the risk of discovering misattributed parentage. 
Approximately 90% of sampled forms explained the purpose for WES and described 
the results to be included in the report. The benefits and risks of WES were 
explained in 83% of consent forms, and the same frequency disclosed that the 
laboratory may use the de-identified data for sharing with national DNA databases. 
Seventy-two percent of forms stated who may have access to the sequence data. 
Approximately 60% included a request to use the sample for research purposes. 
One-half of all forms discussed the possibility for follow-up communication if a new 
interpretation of results is learned, described results to be excluded from the report, 
or explained the approach to returning secondary findings for minors. Nearly 40% 
offered search and disclosure of results for carrier status for recessive disorders. 
Only 11% of consent forms included the recommendation that relevant secondary 
findings should be disclosed to relatives.  
We distinguished between two types of institutions: 1) laboratories affiliated 
with a hospital or university, referred to as “academic” laboratories, and 2) 
laboratories without such affiliation, referred to as “commercial” laboratories 
throughout this report. For academic laboratories, the adherence to each of the 
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individual Bioethics and ACMG recommendations ranged from 20% to 100% (Figure 
4). Among commercial laboratories, the adherence to individual recommendations 
ranged from 0% to 100%. Differences between the two types of laboratories for each 
of the Bioethics and ACMG recommendations were measured using Fisher’s Exact 
test. One statistically significant difference was found. 
 
 
Figure 4. Adherence to Individual Bioethics and ACMG Recommendations 
by Laboratory Type 
p=.05 
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All laboratories, both academic and commercial, disclosed that there would 
be uncertainty of results due to limitations of WES. Approximately 90% of both 
academic and commercial laboratories explained the purpose of the WES and 
described the results that would be contained in the report. One-half of both 
laboratory types discussed the possibility for follow-up communication in light of new 
information about results, and described results that would be excluded from the 
report. 
Every academic laboratory described WES and provided options for seeking 
and reporting the ACMG minimum list, compared to 87.5% of commercial 
laboratories. Ninety percent of academic laboratories specifically described benefits 
and risks of WES compared to 75% of commercial laboratories. Eighty percent of 
academic laboratories described who would have access to the sequence data 
compared to 62.5% of commercial laboratories. Seventy percent of consent forms 
from academic laboratories requested to use the remaining sample for research 
purposes compared to one-half of commercial laboratories. The search and 
disclosure of carrier status for recessive disorders was offered by 60% of academic 
laboratories but only 12.5% of commercial laboratories, a statistically significant 
difference (p=.05). Twenty percent of the academic laboratories recommended that 
relevant secondary findings should be disclosed to relatives but none of the 
commercial laboratories included this recommendation. 
Every commercial laboratory and 90% of academic laboratories defined 
secondary findings, discussed opportunities for pre- and/or posttest genetic 
counseling, stated to whom results would be returned, and disclosed the risk of 
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discovering misattributed parentage. Nearly 88% of commercial laboratories 
explained that the de-identified data may be shared in DNA databases while 80% of 
academic laboratories did so. Nearly 63% of commercial laboratories described the 
policy for returning secondary findings to minors, compared to 40% of academic 
laboratories.  
Other Recommendations for Informed Consent 
We examined guidance pertaining to additional recommendations for 
informed consent identified from the review of literature and preliminary examination 
of forms. The frequency of inclusion of these 5 other recommendations ranged from 
0 to 4 items (Figure 5). The median frequency of inclusion of these 5 other 
recommendations was 1.5 items.  
 
 
Figure 5. Number of Other Recommendations per Laboratory by Laboratory Type 
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One-half of informed consent forms included provisions for WES results to be 
transferred to another health care provider in addition to the ordering clinician 
(Figure 6). Forty-four percent of consent forms provided for return of the raw data file 
to the clinician. The Genetic Information Nondiscrimination Act (GINA) and/or the 
risk of insurance discrimination were explained in 44% of consent forms. The New 
York state statute requiring that samples be destroyed within 60 days of testing was 
acknowledged in 39% of forms. One consent model (6%) informed patients that 
there may be proprietary data that could not be included in the analysis.  
 
 
Figure 6. Frequency of Other Recommendations for Informed Consent 
for 18 Laboratories 
 
 
 
Example language pertaining to these other key points for informed consent 
is presented in Table 6. 
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Table 6 
 
Examples of Content Identified as Addressing Other Recommended Content of Informed Consent Forms 
Recommendation Example Consent Form Content 
Transfer results to other 
health care provider 
I also authorize [the laboratory] to disclose the test results to the ordering physician and any 
other provider I designate. 
Return raw data file The raw data generated from the sequencing may be released to the ordering healthcare 
provider with your consent. 
I authorize the release of raw data to my/my child's healthcare provider and understand that 
any interpretation of the variations identified outside the context of the laboratory report is at 
my/my child's provider's discretion. 
Samples from NY 
destroyed in 60 days 
Samples with New York state origin will be destroyed at the end of testing or no more than 60 
days after the sample was taken, unless a longer period of retention is expressly authorized. 
Risk: Insurance 
discrimination/GINA 
The Genetic Information Nondiscrimination Act (GINA) of 2008 prohibits health insurance 
plans and employers from some discrimination based on genetic information, including the 
results of genetic testing. However, such genetic testing may result in life insurance, disability 
insurance, and/or long-term care insurance discrimination that is not prohibited by law. 
Some genetic information 
may be proprietary 
Certain people and companies have been granted patent rights on certain genes. This gives 
those people and companies the right to prevent others from using those patented genes for 
certain purposes. As a result, [the laboratory] may not be able to analyze or report variants in 
patented gene, even if they are relevant to the disorder in your family. 
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Differences between the two types of laboratories in the adherence to the 
other recommendations for informed consent were examined (Figure 7).  
 
 
Figure 7. Adherence to Other Recommendations for Informed Consent 
by Laboratory Type 
 
 
 
One-half of consent forms from both types of laboratories provided for the 
patient to have results transferred to another health care provider. The return of the 
raw sequence data file was allowed by 62.5% of commercial laboratories but only 
30% of academic laboratories. One-half of commercial laboratories and 40% of 
academic laboratories described GINA and/or the possibility of insurance 
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discrimination as a possible risk. The New York state statute requiring samples to be 
destroyed within 60 days of testing was explained in 62.5% of commercial laboratory 
consent forms but only 20% of academic laboratories. The possibility of proprietary 
genetic information was included in one commercial laboratory’s consent form; none 
of the academic laboratories included this information.  
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CHAPTER 5 
DISCUSSION 
Our results indicate a range of inclusion of the recommendations of the 
Bioethics Commission and ACMG for informed consent of clinical WES. The current 
study is, to the best of our knowledge, the first to systematically examine informed 
consent forms in order to assess the representation of these recommendations. The 
results confirmed our hypothesis that variability would be found in models of 
informed consent for clinical WES.  
The informed consent process is grounded on the ethical principles of respect 
for persons, beneficence, non-maleficence, and autonomy (Bioethics Commission, 
2012; Escobedo, Guerrero, Lujan, Ramirez, & Serrano, 2007; Kole & Feister, 2013; 
OHRP, 1993). An informed consent process that respects the autonomy of patients 
involves providing adequate information so that patients understand the procedure 
and are able to choose the care that is best for them, with regard to their personal 
values (Bioethics Commission, 2012; Escobedo et al., 2007; Kole & Feister, 2013). 
Clinical practice guidelines such as those from the Bioethics Commission and 
ACMG can be helpful in establishing standards, but guidelines do not mandate 
standard of care; adherence is voluntary (Bioethics Commission, 2013). Therefore, it 
is worthwhile to understand how these theoretic ideals are being integrated (or not) 
into real practice so that awareness of the issue and conformance to guidance for 
informed consent of the evolving use of genomic medicine may be encouraged.  
We found that nearly all laboratories in the sample addressed one-half of the 
identified 18 Bioethics Commission and ACMG recommendations. Informed consent 
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forms were generally consistent in describing how and why WES is conducted, 
defining secondary findings and options for receiving these results, describing what 
results would be reported, and explaining that genetic counseling was recommended 
before and after testing. These issues are central to allowing patients to make an 
educated choice to have the clinical WES test, and are reflective of the imperative 
ethical principle of respect for persons. These findings demonstrate that laboratories 
are integrating many of the Bioethics Commission and ACMG recommendations into 
their informed consent process.  
In addition to respect for persons and beneficence, the Bioethics Commission 
(2013) found the ethical principles of justice and fairness, intellectual freedom and 
responsibility, as well as virtues such as honesty, courage, and humility, to be 
particularly applicable to the ethical assessment of secondary findings. Policy and 
ethics professionals are actively debating specific criteria that can be used to 
determine when it is ethically permissible or obligatory for clinicians to disclose (or 
not disclose) secondary findings to patients (Bioethics Commission, 2013; Green et 
al., 2013). A fundamental aspect of this problem is the variation among patients 
about the choice of disclosure of secondary findings. Information that causes anxiety 
for one recipient could empower another recipient in making health-related decisions 
(Bioethics Commission, 2013). The shift from discrete genetic tests toward large-
scale genetic sequencing such as clinical WES increases the likelihood that 
physicians and patients will confront these issues (Bioethics Commission, 2013; 
Crawford et al., 2013). Our results seem to reflect this unsettled debate. 
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We found one-half to 90% of the laboratories sampled did not address the 
Bioethics Commission and ACMG recommendations for informed consent related to 
secondary findings. Fifty percent of consent forms did not discuss the return of 
secondary findings for minors, 61% did not address disclosure of carrier status for 
recessive disorders, and nearly 90% did not plainly recommend that patients should 
disclose relevant secondary findings to relatives. Laboratories that do address the 
ethical dilemmas of disclosing secondary findings for children and relatives 
demonstrate a pioneering approach to informed consent that is not yet well-
established. While the approach of most laboratories to provide non-specific, general 
information about these issues is not unethical, and does respect the patient’s 
freedom and responsibility to make a choice without “paternalistic” guidance, it also 
could infringe on principles of justice and fairness to patients who are not equipped 
to manage these difficult choices and would benefit from unambiguous advice.  
The understanding of results from genome-scale sequencing will change as 
genomic technologies continue to develop and mature (Bioethics Commission, 
2012). Indeed, disclosure of the uncertainty of results for WES was the only 
recommendation item that was included in every consent form, regardless of 
laboratory type. A consent issue related to the uncertainty of results is the need to 
follow up with patients as new knowledge becomes available. However, an 
explanation that the laboratory may re-analyze the data after a certain period of time 
and could re-contact the ordering clinician if a new interpretation of results is learned 
was included in just one-half of consent forms from both types of laboratories. This 
discrepancy deserves further attention in future professional guidance. As genome-
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scale sequencing becomes more ubiquitous, laboratories will need to understand 
their responsibility to apprise patients of new information, and patients will need to 
understand whether or not they are responsible to seek updated results. 
One basic component of informed consent that is well-established and less 
controversial is the disclosure of benefits and risks (Bioethics Commission, 2012). 
However, all consent forms did not include a specific section to explain benefits and 
risks of the procedure. This means that psychological risks such as the patient 
feeling frustrated, angry, disappointed, or depressed related to the results of genetic 
testing was omitted. But it does not mean that risks were not explained. For 
example, instead of explicitly describing risks in a dedicated section of the form, 
some forms included possible risks such as the discovery of misattributed parentage 
in the section describing what results would be returned to the patient. By formatting 
the consent information in this way, laboratories may misguide patients that there 
are no risks, or place more responsibility on the patient to comprehend that a risk is 
possible when it is not specifically stated. This is an aspect of informed consent that 
could be improved with an explicit section with standard language describing risks 
such as psychological distress, possible discovery of misattributed parentage, and 
another often overlooked risk, potential insurance discrimination. 
According to the OHRP, consent processes should reflect the protections 
provided by the Genetic Information Nondiscrimination Act (GINA) in the 
descriptions of risks and protection of confidentiality of the data. GINA’s protections 
prohibit discrimination in employment and health insurance coverage, but do not 
extend to life, disability, or long-term care insurance (Apold & Downie, 2011; OHRP, 
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2009). Discovery and disclosure of secondary findings brings the potential of the 
loss of insurability (Apold & Downie, 2011; Simon et al. 2011). Our study found that 
56% of laboratories did not include information about GINA and/or the risk of 
insurance discrimination. This omission is a potentially serious oversight as it could 
have severe financial and/or health care repercussions for the patient and/or family 
members who receive secondary findings.  
Patients undergoing genome-scale testing may be experiencing a diagnostic 
odyssey, attempting to establish a definite diagnosis for a rare disease or complex 
condition. At the same time, the yield of clinical WES is limited and current ability to 
interpret the data is evolving. Consequently, patients may want to explore other 
clinical opinions of the information and data received from the test. In the context of 
genome-scale sequencing there is a difference between the return of “information” 
and “data”. Information refers to analyzed data interpreted by experts, whereas “raw 
data” refers to the unanalyzed sequence data (Bioethics Commission, 2012). 
Laboratories that permit the transfer of information and/or return of raw data to 
patients can help the patient undergoing a diagnostic odyssey by simplifying access 
to test information and data that may facilitate diagnostic insight from other 
clinicians. In our study, one-half of laboratories included a provision for the transfer 
of results to another health-care provider. Forty-four percent offered to return the raw 
data to the patient, but this allowance differed between types of laboratories. 
Approximately 63% of consent forms from commercial laboratories permitted the 
patient to request the raw data file, but only 30% of academic laboratories did so. 
Professional guidance committees such as the Bioethics Commission and ACMG 
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may want to consider providing advice to professionals for including transfer of 
genetic information and data to patients so that standards for these practices may 
become established and patients receive maximum benefit from the procedure. 
There are legal issues associated with genetic testing that are reflected in our 
analysis of informed consent forms. One example is the New York state law 
requiring that biological samples be destroyed within 60 days of the testing process 
unless the patient consents to a longer period of storage (NY Department of Health, 
2011). This statute was referred to in 39% of the overall sample, but there was 
considerable difference between types of laboratories. Approximately 63% of 
commercial laboratories cited that the sample would be destroyed in 60 days and 
requested approval to store the sample for a longer period of time, whereas only 
20% of academic laboratories included this rule. This discrepancy may reflect the 
service area of the laboratory. While this issue only applies to samples from New 
York, it is possible that more states will enact specific legislation for genetic testing 
and the informed consent process will need to be attentive and responsive to 
changing legal requirements.  
Another legal matter pertains to protections for intellectual property and 
patent laws. As explained by Sherkow & Greely (2015), the US Supreme Court’s 
recent decision in Association for Molecular Pathology v. Myriad Genetics, Inc. 
established that methods of conducting genetic risk-assessment are not eligible for 
patent claims (Sherkow & Greely, 2015). However, patents on the use of specific 
genes for gene therapy continue to be possible and as specific gene therapy 
technologies become commercially available, patent protection for them could come 
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to be significant (Sherkow & Greely, 2015). One consent form in our sample, from a 
commercial laboratory, did include language disclosing the possibility of proprietary 
data which could not be used in the analysis of results. This was a notable exception 
among the sample of consent forms. It is unknown whether this is an artifact of the 
litigation brought by Myriad, Inc. or an innovation that may become more widely 
disseminated into the process of informed consent.  
Implications for Informed Consent 
“Informed consent is a process, not just a form” (OHRP, 1993, p. 1). The 
informed consent process provides a principal opportunity for communication 
between clinicians and patients (Bioethics Commission, 2013). Good clinical care 
includes providing patients with sufficient information to make educated decisions 
about the treatment they receive. This can be challenging for genome-scale tests 
(Crawford et al., 2013). Traditional approaches to informed consent may not be 
compatible with the specific contexts of genomic testing (Simon et al, 2011).  
Our study demonstrates that patients receive different information for the 
consent of clinical WES depending on which laboratory conducts the procedure. In 
order to improve the quality and consistency of communication between clinicians 
and patients, practitioners should collaborate to improve the process of informed 
consent by developing clear and consistent guidelines for consent forms (Bioethics 
Commission, 2012, 2013). The recommendations of the Bioethics Commission, 
ACMG, and exemplars from practitioners provide a framework for this task. Our 
study results may be used as a template for informed consent that addresses 18 
recommendations from the Bioethics Commission and ACMG and 5 additional 
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elements of consent. The examples of informed consent content displayed in Tables 
5 and 6 serve as a template for a standard model of informed consent. A common 
set of consent elements will help to serve the ethical principle of respect for persons. 
In addition, development of standardized systems and infrastructure to enable health 
information exchange so that data can be aggregated and studied is advocated to 
support the emerging practice of personalized medicine and the learning healthcare 
system (Aronson & Rehm; Bioethics Commission, 2012; Reinke, 2015; Wiley et al., 
2016). 
Study Limitations  
The study had a limited scope, including only informed consent forms for 
clinical WES that were available for download. Additional laboratories were identified 
as providing clinical WES that did not post their informed consent forms online. The 
scope of inclusion of Bioethics Commission and ACMG recommendations for ACMG 
may be different among laboratories that restrict access to their informed consent 
forms. The generalizability of the findings of this study is restricted to publicly 
available consent forms. The small sample size limited the statistical power to detect 
meaningful differences. 
The study identified laboratories that conduct clinical WES by searching 
online genetic test registries. Registration in databases such as the National Center 
for Biotechnology Information’s Gene Test Registry is voluntary, thus the sampling of 
laboratories reflects only those that choose to submit information to such databases. 
It is unknown how many laboratories actually conduct the clinical WES procedure. 
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The study sample may be biased toward larger laboratories and exclude small or 
private organizations that do not participate in genetic test registration databases. 
Another limitation is that the content analysis was conducted by a single 
evaluator. While steps were taken to improve the validity and reliability of the ratings 
by repeating the assessment of forms three times, the analysis lacks inter-rater 
reliability. It is possible that the interpretation of consent language could be different 
by another analyst. In order to make transparent the content analysis criteria used 
by the investigator, the results include examples of content that were identified as 
addressing each recommendation item. 
Further Study 
Further study of informed consent forms used for clinical WES is needed. 
Future studies that include consent forms from laboratories that do not provide 
online access to their forms and/or are not listed in genetic test registries is needed 
to better evaluate the spectrum of informed consent procedures. The analysis of 
informed consent guidance would also be augmented by surveys of clinicians and 
patients to learn opinions and preferences for the recommendations of the Bioethics 
Commission, ACMG, and other elements of informed consent.  
Conclusion 
We observed considerable variability in the content of informed consent forms 
among the sample of 18 laboratories. This analysis can be useful to laboratories that 
provide clinical WES to improve informed consent forms so that they are in 
alignment with recommendations from the Bioethics Commission and ACMG. The 
development of a more standardized informed consent process could improve 
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communication between clinicians and patients, increase understanding of genetic 
testing, and allow for increased data sharing.  
 49 
 
 
APPENDIX A 
RECOMMENDATIONS OF THE PRESIDENTIAL COMMISSION  
FOR THE STUDY OF BIOETHICAL ISSUES:  
Informed Consent: Privacy and Progress in  
Whole Genome Sequencing  
Recommendation 3.1 
Researchers and clinicians should evaluate and adopt robust and workable 
consent processes that allow research participants, patients, and others to 
understand who has access to their whole genome sequences and other data 
generated in the course of research, clinical, or commercial sequencing, and to 
know how these data might be used in the future. Consent processes should 
ascertain participant or patient preferences at the time the samples are obtained. 
Recommendation 3.2 
The federal Office for Human Research Protections or a designated central 
organizing federal agency should establish clear and consistent guidelines for 
informed consent forms for research conducted by those under the purview of the 
Common Rule that involves whole genome sequencing. Informed consent forms 
should: 1) briefly describe whole genome sequencing and analysis; 2) state how the 
data will be used in the present study, and state, to the extent feasible, how the data 
might be used in the future; 3) explain the extent to which the individual will have 
control over future data use; 4) define benefits, potential risks, and state that there 
might be unknown future risks; and 5) state what data and information, if any, might 
be returned to the individual. 
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Recommendation 3.3 
Researchers, clinicians, and commercial whole genome sequencing entities 
must make individuals aware that incidental findings are likely to be discovered in 
the course of whole genome sequencing. The consent process should convey 
whether these findings will be communicated, the scope of communicated findings, 
and to whom the findings will be communicated. 
Recommendation 3.4 
Funders of whole genome sequencing research should support studies to 
evaluate proposed frameworks for offering return of incidental findings and other 
research results derived from whole genome sequencing. Funders should also 
investigate the related preferences and expectations of the individuals contributing 
samples and data to genomic research and undergoing whole genome sequencing 
in clinical care, research, or commercial contexts.   
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APPENDIX B 
RECOMMENDATIONS OF THE PRESIDENTIAL COMMISSION  
FOR THE STUDY OF BIOETHICAL ISSUES:  
Anticipate and Communicate: Ethical Management of  
Incidental and Secondary Findings in the Clinical,  
Research, and Direct-to-consumer Contexts 
 
Recommendation 1 
Clinicians, researchers, and direct-to-consumer providers should describe to 
potential recipients incidental and secondary findings that are likely to arise or be 
sought from the tests and procedures conducted. Practitioners should inform 
potential recipients about their plan for disclosing and managing incidental and 
secondary findings, including what findings will and will not be returned. 
Recommendation 6 
Clinicians should make patients aware that incidental and secondary findings 
are a possible, or likely, result of the tests or procedures being conducted. Clinicians 
should engage in shared decision making with patients about the scope of findings 
that will be communicated and the steps to be taken upon discovery of incidental 
findings. Clinicians should respect a patient’s preference not to know about 
incidental or secondary findings to the extent consistent with a clinician’s fiduciary 
duty.  
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APPENDIX C 
AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS 
POLICY STATEMENT:  
Points to Consider for Informed Consent for  
Genome/Exome Sequencing 
 
1. Before initiating GS/ES, counseling should be performed by a medical geneticist 
or an affiliated genetic counselor and should include written documentation of 
consent from the patient. 
2. Incidental/secondary findings revealed in either children or adults may have high 
clinical significance for which interventions exist to prevent or ameliorate disease 
severity. Patients should be informed of this possibility as a part of the informed 
consent process. 
3. Pretest counseling should include a discussion of the expected outcomes of 
testing, the likelihood and type of incidental results that may be generate, and the 
types of results that will or will not be returned. Patients should know if and what 
types of incidental findings may be returned to their referring physician by the 
laboratory performing the test. 
4. Patients should be counseled regarding the potential benefits and risks of 
GS/ES, the limitations of such testing, potential implications for family members, 
and alternatives to such testing. 
5. GS/ES is not recommended before the legal age of majority except for: 
a. Phenotype-driven clinical diagnostic uses; 
b. Circumstances in which early monitoring or interventions are available and 
effective; or 
c. Institutional review-board-approved research. 
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6. As part of the pretest counseling, a clear distinction should be made between 
clinical and research-based testing. 
7. Patients should be informed as to whether individually identifiable results may be 
provided to databases, and they should be permitted to opt out of such 
disclosure. 
8. Patients should be informed of policies regarding re-contact of referring 
physicians as new knowledge is gained about the significance of particular 
results. 
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APPENDIX D 
AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS 
POLICY STATEMENT:  
Updated Recommendations Regarding Analysis and  
Reporting of Secondary Findings in Clinical  
Genome-scale Sequencing 
 
 When clinical genome-scale (e.g., whole-exome sequencing, whole-genome 
sequencing) sequencing is performed, written informed consent should be 
obtained by a qualified genetics health-care professional describing the nature of 
the test and addressing points such as interpretive uncertainty, privacy, possible 
impact on other family members, and the inevitable generation of data not 
immediately relevant to the clinical indication for sequencing. At the time of 
testing, the patient should be made aware that, regardless of the specific 
indication for testing, laboratories will routinely analyze the sequence of a set of 
genes deemed to be highly medically actionable so as to detect pathogenic 
variants that may predispose to a severe but preventable outcome. 
 Patients should be informed during the consent process that, if desired, they may 
opt out of such analysis. However, they should also be made aware at that time 
of the ramifications of doing so. 
 In accordance with the recent recommendations of the Presidential Commission 
for the Study of Bioethical Issues, as well as a lack of clear consensus in the 
ACMG membership survey administered in January 2014, the board 
recommends that the same policy should be adhered to in children as in adults; 
i.e., analysis of a set of selected genes to identify pathogenic variants associated 
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with severe but preventable disease should be routinely performed. Parents 
should have the option during the consent process to opt out of such analysis. 
 At this time, given the practical concerns and inherent difficulty of counseling 
patients about the features of each disorder and every gene on an ever-changing 
list, it is not feasible for patients to be offered the option of choosing a subset of 
medically actionable genes for analysis. Thus, the decision regarding routine 
analysis should apply to the entire set of genes deemed actionable by the 
ACMG. 
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